Question 1

What is Axsome Therapeutics?

Accepted Answer

Axsome Therapeutics is a Company.

Question 2

How often does Axsome Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Axsome Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Jun 01, 2026.

Question 4

When was Axsome Therapeutics last mentioned in news?

Accepted Answer

Last active on Jun 26, 2026.

Question 5

What is Axsome Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Axsome Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Axsome Therapeutics?

Accepted Answer

Axsome Initiates Solriamfetol ADHD Trial (Jun 26, 2026, 7 articles).

Question 8

How did the "Axsome Initiates Solriamfetol ADHD Trial" event impact Axsome Therapeutics?

Accepted Answer

Axsome Therapeutics initiated the FOCUS-3 Phase 3 trial for solriamfetol in adolescents with ADHD, which could expand its product portfolio and market reach if successful.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.